Iron-deficiency clinical trials at UCSD
1 in progress, 1 open to new patients
open to eligible people ages 18 years and up
The primary objective of this study is to determine the efficacy and safety of iron therapy using intravenous (IV) ferric carboxymaltose (FCM), relative to placebo, in the treatment of participants in heart failure with iron deficiency and with a reduced ejection fraction.
San Diego, California and other locations